Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131I Treatment.

Trial Profile

Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131I Treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2016

At a glance

  • Drugs Axitinib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Mar 2016 Results (pooled analysis of this and other study, n = 98) assessing exposure-response relationship presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 29 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT00094055)
    • 29 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT00094055)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top